Tesamorelin vs Ipamorelin

Growth hormone research peptides fall into two families. Knowing which family a compound belongs to changes how you design a protocol. Tesamorelin and Ipamorelin sit on opposite sides of that divide.

Tesamorelin is a synthetic peptide of 44 amino acids. It copies growth hormone-releasing hormone (GHRH). The FDA approved it in 2010 as Egrifta SV. It treats fat loss seen in HIV patients. It binds GHRH receptors on somatotroph cells (pituitary cells that make growth hormone). This triggers the body's own pulsatile growth hormone release [PMID: 20826567].

A chemical group at one end blocks a degrading enzyme. This makes the peptide stronger and more stable than natural GHRH. Its half-life is 26 to 38 minutes. Daily injection is standard.

Ipamorelin is a pentapeptide (five amino acids: Aib-His-D-2-Nal-D-Phe-Lys-NH2). It activates the ghrelin growth hormone secretagogue (GHS) receptor. Novo Nordisk first developed it. It uses a different receptor pathway than Tesamorelin.

Ipamorelin is known for selectivity. Unlike older GHS compounds (such as GHRP-6 or pralmorelin), it does not raise ACTH, cortisol, prolactin, FSH, LH, or TSH [PMID: 21480850]. Its half-life is about 2 hours.

The key difference is mechanism, not strength. Tesamorelin copies the body's GHRH signal. Ipamorelin copies ghrelin. Both raise growth hormone, but they use different receptors and trigger different signals.

Your choice depends on what you are measuring. Let's look at the details.

Tesamorelin and Ipamorelin raise growth hormone through different receptor systems.

Tesamorelin binds the GHRH receptor (GHRH-R) on somatotrophs (pituitary cells that make growth hormone). It turns on the Gs cAMP pathway. This copies the body's natural GHRH route: it raises growth hormone gene transcription, growth hormone synthesis, and pulsatile growth hormone release (release in bursts).

Because Tesamorelin uses the same receptor as natural GHRH, it keeps the body's pulse pattern. It amplifies the natural signal rather than replacing it [PMID: 20826567].

Ipamorelin binds the growth hormone secretagogue receptor (GHS-R1a). Ghrelin, the hunger hormone, uses this same receptor. The Gq pathway turns on. This releases calcium inside the cell and causes growth hormone release. This is a parallel route to GHRH. Both end at growth hormone release, but they use different receptors [PMID: 19956008].

Their side effect profiles differ. Tesamorelin mainly affects growth hormone and IGF-1 (a growth factor made in the liver). Ipamorelin could raise ACTH and cortisol, as GHRP-6 does. But its design blocks this. Clinical data show no big rise in ACTH or cortisol [PMID: 9758556].

Both raise IGF-1, but the timing differs. Tesamorelin raises IGF-1 steadily, since it copies natural GHRH. Ipamorelin raises IGF-1 through growth hormone release. The size of this effect can vary with dose and person.

Both Tesamorelin and Ipamorelin are synthetic peptides. Both raise the body's own growth hormone, rather than adding hormone from outside.

This is a shared trait: both work with the body's existing growth hormone system. Both raise natural release rather than overriding it. The body's own negative feedback (IGF-1 slows growth hormone release) stays in place. This lowers the risk of unchecked growth hormone rise.

Both use subcutaneous injection (injection under the skin). Both need regular dosing, since their half-lives are short. Both raise blood growth hormone and, later, IGF-1. Both are well-tolerated. The most common side effect for each is an injection site reaction.

Neither is anabolic in a direct way. They do not bind androgen receptors (the receptors male sex hormones use). They do not directly raise muscle protein synthesis. Their body composition effects come through the growth hormone / IGF-1 axis. This axis raises fat breakdown and protein synthesis.

Both are peptides, not small molecules. Enzymes (proteases) break them down. They do not build up in tissue over time.

For research, both are useful tools. They let researchers study raised growth hormone and IGF-1 without adding outside hormone. This helps us understand how the growth hormone system works.

The receptor pathway is the key difference. Tesamorelin uses GHRH receptors. This is the body's own route, and it comes in pulses. Ipamorelin uses ghrelin (GHS) receptors. This is a parallel route with its own signals. This shapes all the side effects, selectivity, and use.

FDA status sets them apart. Tesamorelin is FDA-approved (Egrifta SV, 2010). It treats excess belly fat seen in HIV patients. This approval came with Phase III safety and efficacy data, long-term follow-up, and post-marketing checks. Ipamorelin reached Phase II trials for gut slowing after surgery (Novo Nordisk and Helsinn Therapeutics). It was dropped for lack of effect. It remains a research peptide with no approved medical use.

Their selectivity differs. Ipamorelin was designed to avoid raising ACTH, cortisol, prolactin, and gonadotropins. This is its main research edge over older GHS compounds. Tesamorelin is also fairly selective. But it can interact with a damaged pituitary. It is barred in patients with pituitary tumors or low pituitary function.

Half-life and dosing differ. Tesamorelin's half-life is 26 to 38 minutes. It needs one daily injection at a fixed 2 mg dose. Ipamorelin's half-life is about 2 hours. Research often uses 2 to 3 daily doses, or single doses. Its longer half-life keeps growth hormone up longer per dose.

Body composition research differs. Tesamorelin has solid clinical data. It lowers visceral adipose tissue (VAT, fat around organs). This outcome formed the basis for its FDA approval. Ipamorelin's body composition data are thinner. They come mostly from animal studies and small human studies. But growth hormone rise is well-documented.

Cost and access differ. Tesamorelin is a branded drug and costs more. Ipamorelin is an unregulated research peptide. It is easy to find and costs less, but quality varies by seller. One side buys regulatory certainty. The other buys flexibility.

Choose Tesamorelin if your research focuses on reducing belly fat, on the GHRH receptor route, or if you need an FDA-approved compound with extensive clinical trial data. Tesamorelin fits protocols that need physiological GHRH agonism (copying the body's own GHRH signal), clear pharmacokinetics (how the body handles the drug), and a well-studied safety profile. Its clinical data on visceral adipose tissue (fat around organs) reduction are the strongest among growth hormone secretagogues.

Choose Ipamorelin if your research needs selective growth hormone release without rises in ACTH, cortisol, or prolactin. Its clean selectivity profile fits studies that must isolate growth hormone effects from other pituitary hormone changes. Its longer half-life (2 hours vs. 26 to 38 minutes) also fits protocols that need sustained growth hormone rise per dose.

For receptor route studies, the choice is direct. Use Tesamorelin for GHRH-R work. Use Ipamorelin for GHS-R1a (ghrelin receptor) work. They are not interchangeable. They use different receptors and trigger different signals inside the cell.

Some researchers use both at once. GHRH and ghrelin routes both raise growth hormone. They do so in a synergistic way (each makes the other stronger). Giving a GHRH analogue (a copy) with a ghrelin mimetic can raise growth hormone more than either alone. The two intracellular routes (cAMP/PKA and PLC/PKC) boost each other in the somatotroph cell. Some in the research field call this a "GH secretagogue stack."